Low within-and between-day variability in exposure to new insulin glargine 300 U/ml

被引：0

作者：

Becker, R. H. ^{[1
]}

Nowotny, I. ^{[1
]}

Teichert, L. ^{[1
]}

Bergmann, K. ^{[1
]}

Kapitza, C. ^{[2
]}

机构：

[1] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany

[2] Profil, Neuss, Germany

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

953

引用

页码：S390 / S390

页数：1

共 50 条

[21] Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs [J].

Fink, H. ;

Herbert, C. ;

Gilor, C. .

DOMESTIC ANIMAL ENDOCRINOLOGY, 2018, 64 :17-30

[22] Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL [J].

Lindauer, Klaus ;

Becker, Reinhard .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (01) :1-10

[23] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA [J].

Bogdanovic, M. ;

Fournier, M. ;

Vitezic, D. .

VALUE IN HEALTH, 2018, 21 :S131-S132

[24] COST-UTILITY EVALUATION OF INSULIN GLARGINE (300 U/ML) VERSUS INSULIN GLARGINE (100 U/ML) AND INSULIN DEGLUDEC (100 U/ML) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SERBIA [J].

Mihajlovic, J. ;

Bogdanovic, M. ;

Foumier, M. .

VALUE IN HEALTH, 2017, 20 (09) :A481-A481

[25] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA [J].

Bogdanovic, M. ;

Mihajlovic, J. ;

Fournier, M. .

VALUE IN HEALTH, 2018, 21 :S133-S133

[26] A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine [J].

Dailey, G. ;

Lavernia, F. .

DIABETES OBESITY & METABOLISM, 2015, 17 (12) :1107-1114

[27] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus [J].

Yang, K. -H. ;

Tseng, C. -T. ;

Chen, L. -C. ;

Chen, P. -C. .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) :310-310

[28] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus [J].

Goldman, Jennifer ;

White, John R., Jr. .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) :1153-1161

[29] Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300) [J].

Mader, Julia K. ;

Goelz, Stefan ;

Bilz, Stefan ;

Bramlage, Peter ;

Danne, Thomas .

BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (04)

[30] Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats [J].

Gilor, C. ;

Culp, W. ;

Ghandi, S. ;

do Carmo Emidio e Silva, J. A. ;

Ladhar, A. ;

Hulsebosch, S. .

DOMESTIC ANIMAL ENDOCRINOLOGY, 2019, 69 :19-29

← 1 2 3 4 5 →